Key Takeaways
- Astellas is a top-20 global pharma formed in 2005 by the Yamanouchi plus Fujisawa merger, headquartered in Tokyo Chuo with about 15,000 employees worldwide
- The three hiring tracks (Japan HQ, Astellas Pharma US in Northbrook Illinois, and Astellas Pharma Europe in Addlestone and Leiden) are largely separate pipelines with different expectations and compensation structures
- All regions use SAP SuccessFactors Recruiting at careers.astellas.com, so optimize your resume for clean parsing and exact keyword matching
- Japan HQ interviews expect Japanese-format rirekisho and shokumu-keirekisho documents, formal business etiquette, and a credible tenure narrative
- US and EMEA interviews run closer to standard Western biopharma behavioral formats but retain Japanese-parent influences on decision speed and consensus building
- The 2024 Iveric Bio acquisition, the 2024 Vyloy approvals, and the looming Xtandi patent cliff across 2027-2028 are live internal topics that candidates should understand
- CEO Naoki Okamura, who succeeded Yasushi Okada in April 2024, has publicly framed his tenure around post-Iveric integration and Xtandi lifecycle defense
- Honest framing wins: candidates who acknowledge the Xtandi cliff risk and Iveric integration overhang while articulating their contribution outperform candidates who recite marketing language
- The classic Japanese pharma peer set (Takeda, Daiichi Sankyo, Ono) is where most declined offers go, so understand how you would answer which you prefer and why before the final round
About Astellas Pharma
Astellas Pharma Inc. (TSE: 4503) is a Tokyo-headquartered global pharmaceutical company formed in April 2005 through the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical, two century-old Japanese drug makers whose combined franchises in urology, immunosuppression, and anti-infectives created one of Japan's top three pharmaceutical companies overnight. Headquartered at 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, Astellas employs approximately 15,000 people across more than 70 countries and operates major hubs in Northbrook, Illinois (Americas, the legacy Fujisawa Healthcare campus), Leiden in the Netherlands (EMEA), and Singapore. The company sits within the top 20 global pharma rankings by revenue and has built its modern identity around four commercial franchises: Xtandi (enzalutamide, a prostate cancer therapy co-developed and co-promoted with Pfizer and Medivation's successor), Prograf (tacrolimus, the transplant immunosuppressant that anchors the legacy Fujisawa portfolio), Mycamine (the antifungal echinocandin), and Vyloy (zolbetuximab, a first-in-class Claudin 18.2 targeted therapy for gastric cancer approved in Japan, the US, and the EU across 2024). In June 2024 Astellas closed its $5.9 billion acquisition of Iveric Bio, bringing Izervay (avacincaptad pegol) into the portfolio as a second-line therapy for geographic atrophy secondary to age-related macular degeneration and establishing ophthalmology as a fifth strategic pillar alongside oncology, transplant, ophthalmic, and women's health. The integration has been uneven: Izervay's label and competitive position against Apellis's Syfovre have created near-term revenue pressure, and the company took sizeable impairments on the Iveric goodwill during FY2024, which candidates should understand is an active topic inside the business. Leadership changed in April 2024 when Naoki Okamura succeeded Yasushi Okada as Representative Director, President and CEO; Okamura previously served as CFO and Chief Strategy Officer and has publicly framed his tenure around executing the post-Iveric integration, defending Xtandi's lifecycle as composition-of-matter patents expire across 2027-2028 in the US and earlier in Europe, and scaling the genetic medicine pipeline (AT132 for XLMTM, AAV-delivered therapies) that Astellas acquired through its Audentes Therapeutics purchase. Candidates evaluating Astellas should go in clear-eyed about the Xtandi patent cliff, the Iveric integration overhang, and the classic Japanese-pharma tenure culture at the Tokyo HQ, while recognizing the company's genuine strength in transplant medicine, its oncology momentum with Vyloy, and the deeper career runway available on the global operating model than at many other Japanese pharma peers.
ATS System: SAP SuccessFactors Recruiting
Astellas runs its global careers portal at careers.astellas.com on SAP SuccessFactors Recruiting, with job postings hosted on SuccessFactors Career Site Builder and media assets served from rmkcdn.successfactors.com. SuccessFactors parses uploaded resumes into a structured candidate profile and uses keyword and field matching to rank applicants for recruiter review.
- Upload a PDF or DOCX resume with a clean single-column layout and selectable text
- After upload, open the parsed profile preview and correct any employer, title, or date extraction errors before submitting
- Match keywords in the job description exactly for therapeutic area, molecule, and regulatory terms, because SuccessFactors is a literal keyword matcher
- Complete every required profile field including work authorization and location preferences; incomplete profiles are filtered out
- Set up a job agent for the Astellas career site to get notified when new requisitions open in your function
Interview Culture
Astellas interview culture varies sharply by region and is one of the places where candidates most commonly mis-read the company.
At the Tokyo HQ, interviews follow classic Japanese large-cap pharma formality: arrive ten minutes early, exchange business cards (meishi) with both hands, bow rather than shake hands unless the interviewer extends theirs first, and match the interviewer's language choice. Shinsotsu interviews for new graduates feel like a structured cultural assessment as much as a skills check, with group discussions (group discussion or GD rounds), SPI aptitude testing, and multi-round panels where quiet composure and clear reasoning matter more than assertive self-promotion. For mid-career HQ roles, expect to explain your reason for leaving your current employer (tenshoku riyu) without criticizing your prior company, which is non-negotiable etiquette in Japanese hiring and a common way candidates inadvertently disqualify themselves. Tenure culture is real: a two or three year stint in your last role can read as short, and candidates with multiple sub-three-year moves should be prepared to explain the narrative coherently. Astellas Pharma US at the Northbrook, Illinois campus and the Cambridge, Massachusetts offices operates much closer to a standard US biopharma culture, with behavioral interviewing, STAR-format questions, and more direct negotiation norms, but retains meaningful Japanese-parent influence on decision speed, consensus-building (nemawashi), and cross-regional approval chains that candidates coming from pure US biotech sometimes find slower than expected. In EMEA, Leiden and Addlestone interviews fall between the two, with a more European professional-services tone and fluent English throughout. Across all three regions, the post-2024 Iveric Bio integration is a live topic inside the business: ophthalmology candidates should expect questions about Izervay's competitive position against Syfovre and about their willingness to work through a still-forming commercial and medical affairs organization. Oncology and rare-disease candidates should expect focused technical discussions on Xtandi lifecycle management, Vyloy launch execution in Claudin 18.2 positive gastric cancer, and the AAV genetic medicine pipeline inherited from the Audentes acquisition. Across every region, Astellas interviewers weigh values alignment against the published Integrity, Innovation, and Impact framework, and candidates who explicitly connect their past work to patient outcomes (not just commercial metrics) consistently advance further.
What Astellas Pharma Looks For
- Deep expertise in at least one of Astellas's core therapeutic areas: oncology, transplant, ophthalmology, rare disease, or women's health
- Clear patient-outcomes framing, not just commercial or technical metrics, in how you describe your past work
- Demonstrated ability to operate across regions, cultures, and functions in a matrixed global organization
- Values alignment with the published Integrity, Innovation, and Impact framework, with concrete examples
- For Japan HQ roles, tenure stability and a clear, non-critical narrative for each past role transition
- For R&D, specific experience with the molecule classes in Astellas's portfolio or late-stage clinical development under PMDA, FDA, or EMA
- For commercial and MR roles, quantified share, rank, and growth metrics and documented product launch experience
- For global functions, strong written and spoken English and, ideally, working Japanese sufficient to communicate with HQ counterparts
Frequently Asked Questions
What does Astellas pay for new graduates (shinsotsu) in Japan?
Astellas Japan shinsotsu compensation for FY2024 starting salaries was in the range of 250,000 to 270,000 JPY monthly base for undergraduates with additional uplift for masters and PhD holders, which annualizes to roughly 4 to 5 million JPY in the first year including biannual bonuses. Total compensation for shinsotsu typically reaches 6 to 10 million JPY by the three-to-five year mark as MR or HQ junior staff progress through the grade bands. Shinsotsu base pay is set on a posted scale and is not negotiable.
What does Astellas Pharma US pay for mid-career roles in Northbrook and Cambridge?
Astellas Pharma US compensation tracks the US biotech and mid-to-large pharma market. Mid-career associate and senior scientists typically land in the 130,000 to 180,000 USD base range; associate and senior directors in commercial, medical affairs, and R&D typically land in the 180,000 to 220,000 USD base range with 20 to 35 percent target bonus and long-term incentives in RSUs and performance shares. Actual offers vary by function, level, and Illinois versus Massachusetts location, and Cambridge-based R&D roles tend to price at the upper end of the Boston biotech market.
Why do Astellas offers often get declined for Takeda, Daiichi Sankyo, or Ono?
Candidates most commonly cite three reasons: Takeda offers larger global platform exposure and a more aggressive oncology and gastroenterology pipeline; Daiichi Sankyo has momentum from its Enhertu partnership with AstraZeneca and the broader DXd antibody-drug conjugate platform; and Ono is seen as having a more entrepreneurial culture around Opdivo lifecycle and novel modalities. Astellas counters with stronger transplant franchise depth, the Iveric ophthalmology bet, and Vyloy in Claudin 18.2 gastric cancer, but candidates weighing pipeline optionality sometimes choose the peers.
Is the Xtandi patent cliff a real career risk?
Yes and no. Xtandi composition-of-matter protection expires in the US around 2027-2028 and earlier in parts of Europe, and Astellas has publicly acknowledged this is a major revenue event the company is planning around. For roles tied to Xtandi marketing, sales, or MSL work, the franchise will be smaller in 2029 than in 2024 and headcount plans will follow. For R&D and other franchises such as Vyloy, Izervay, transplant, and the genetic medicine pipeline, the cliff is a tailwind for internal prioritization. Candidates should weight role exposure, not company exposure, when evaluating risk.
How did the Iveric Bio acquisition change Astellas, and should I worry about integration?
The June 2024 closing of the 5.9 billion USD Iveric Bio acquisition gave Astellas Izervay for geographic atrophy and established ophthalmology as a fifth pillar. The integration has been uneven: Izervay's label language and competition against Apellis's Syfovre have created revenue pressure, and Astellas recorded meaningful goodwill impairments during FY2024. For candidates joining the ophthalmology organization in particular, expect a still-forming commercial and medical affairs structure and a more dynamic environment than legacy Astellas functions.
Is Japanese language proficiency required for Astellas global roles?
It depends on the role base. Roles based at the Tokyo HQ are functionally Japanese-first even when designated global; expect to read internal documents, attend meetings, and receive performance feedback in Japanese, though English-only global roles do exist and are explicitly labeled. Roles based in Northbrook Illinois, Cambridge Massachusetts, Addlestone UK, and Leiden NL do not require Japanese, but working Japanese is a noticeable accelerator for any position with HQ counterparts. For MR and Japan commercial roles, native-level Japanese is non-negotiable.
How long does the Astellas interview process take from application to offer?
Typical timelines are four to eight weeks for Astellas Pharma US and Astellas Pharma Europe mid-career roles from application to offer, with two to four interview rounds after the recruiter screen. Japan HQ mid-career timelines run six to ten weeks and can stretch longer because of consensus-building approval chains (nemawashi) that the US and EMEA have largely flattened. Shinsotsu cycles run on the Japan new-graduate calendar with offers issued in summer for the following April start.
Does Astellas sponsor US work visas?
Astellas Pharma US sponsors H-1B transfers, H-1B cap filings for selected roles, and green cards for retained talent, consistent with large US pharma norms. Visa support is most commonly extended for R&D, medical affairs, biostatistics, and specialized commercial roles. Entry-level sales and administrative roles are less likely to receive sponsorship. Confirm sponsorship status with the recruiter on the initial screen rather than after the final round.
What is Astellas's stance on remote and hybrid work?
Astellas operates a hybrid model across all regions as of 2025-2026, with most commercial and corporate roles expected onsite two to three days per week. R&D laboratory roles are onsite daily. Tokyo HQ runs on a hybrid policy that varies by department but generally expects Tuesday through Thursday in the Nihonbashi office. Northbrook and Cambridge follow similar three-day hybrid norms. Fully remote roles exist but are a small minority and typically tied to specific function-level decisions.
What is the best path from university into Astellas?
For Japan, the strongest path is the shinsotsu recruitment cycle in your final university year, targeting either the MR track (commercial) or the R&D scientist track, with aptitude testing and group discussions as key selection stages. For the US, the strongest path is a PharmD, PhD, or MD placement into US medical affairs or R&D, often through internships at Astellas Pharma US or Astellas Institute for Regenerative Medicine (AIRM). For EMEA, new-graduate entry is most common through country affiliate commercial or medical graduate schemes in the UK and NL.
Open Positions
Astellas Pharma currently has 1 open positions.
Related Resources
Sources
- Astellas Pharma Inc. Corporate Overview — Astellas Pharma Inc.
- Astellas Pharma Inc. Careers — Astellas Pharma Inc.
- Astellas Completes Acquisition of Iveric Bio — Astellas Pharma Inc.
- Astellas Announces New Representative Director, President and CEO Naoki Okamura — Astellas Pharma Inc.
- VYLOY (zolbetuximab) FDA Approval for Gastric Cancer — US Food and Drug Administration
- Xtandi (enzalutamide) Prescribing Information and Franchise Partnership — Astellas Pharma US, Inc.
- Astellas Pharma FY2024 Annual Report and Financial Results — Astellas Pharma Inc.
- SAP SuccessFactors Recruiting Overview — SAP SE
